Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib PK with PPI in Hospitalized COVID-19
NCT04497948Phase 1Terminated
- Sponsor
- Acerta Pharma
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of acalabrutinib in coronavirus disease 2019 (COVID-19), sponsored by Acerta Pharma. Primary endpoints: Area Under the Concentration-time Curve From 0 to 12 Hours, Area Under the Concentration-time Curve From 0 to Time to Last Quantifiable Concentration at Day 5 and 1 more. Started Sep 2020; status: terminated.
02
Drugs
acalabrutinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04497948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04497948.